OBIO Announces Expansion of Early Adopter Health Network Partnerships

OCTOBER MARKS THIRD EAHN™ COHORT SELECTION TO COMMERCIALIZE INNOVATIVE TECHNOLOGIES

September 29, 2021 – TORONTO, ON – The Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit organization dedicated to advancing health technology innovation and commercialization, is proud to announce the growth and expansion of its Early Adopter Health Network (EAHN™) partnerships, together with the upcoming selection round of its new cohort.

With more than 18 healthcare members and 11 innovation organization partners from across Canada, the EAHN™ has grown into Canada’s premier health science market acceleration program since its launch in early 2020. Now, OBIO® will be hosting its third cohort network day in October, where innovative companies will meet with healthcare organizations prior to launching new EAHN™ projects later this year.

“We are delighted to expand the EAHN™ with the engagement of so many leading healthcare organizations and with the support of our innovation organization partners,” said Gail Garland, President & CEO of OBIO®. “Growing and maintaining a robust and globally competitive domestic health science industry ecosystem here in Canada requires partnerships and collaborations to get the job done.”

Through the EAHN™, which is supported by the Federal Economic Development Agency of Southern Ontario, OBIO® provides project management and financial support to evaluate technologies in the real-world setting and facilitate their broad adoption into the health system. They connect leading-edge, scaling health science companies with healthcare organizations, providing an opportunity for innovators to access local markets before expanding globally, as well as a strong reason to anchor themselves in Canada.

Driven by OBIO’s unique capacity to pair commercial-ready technologies with clinical end-users who want to deliver improved care at any health institution, the goal for the EAHN™ is to become early adopters of homegrown medical technology and help streamline the procurement process. Through a collaborative and comprehensive approach, EAHN™ addresses both the “push” and “pull” factors of what industry has developed and what burdened hospitals are trying to address. This allows the EAHN™ to catalyze change by delivering improved patient care more efficiently while opening the door to a new health-care economy that benefits Canadians and Canadian companies alike.

OBIO® would like to thank and recognize the following organizations for their involvement and support in the EAHN™:

EAHN™ Healthcare Members:

  • Baycrest

  • Bruyère

  • Centre for Addiction and Mental Health (CAMH)

  • Hamilton Health Sciences

  • Health Sciences North

  • Hôtel-Dieu Grace Healthcare

  • Joseph Brant Hospital

  • Kingston Health Sciences Centre

  • Michael Garron Hospital

  • North York General Hospital

  • Southlake Regional Health Centre

  • St. Mary’s General Hospital

  • The Ottawa Hospital

  • Unity Health Toronto

  • University Health Network (UHN)

  • West Park Healthcare Centre

  • Winchester District Memorial Hospital

  • Women’s College Hospital

EAHN™ Innovation Organization Partners:

  • Carleton University

  • Clinical Trials Ontario

  • Invest Ottawa

  • Life Sciences British Columbia

  • Montréal InVivo

  • Ontario Institute for Regenerative Medicine

  • Ryerson Biomedical Zone

  • SOSCIP Consortium

  • StarFish Medical

  • Stem Cell Network

  • Synapse Life Science Consortium

For more information about OBIO’s EAHN™, or if you are interested in being part of the network, please contact Dr. Jeff Aramini at jeffaramini@obio.ca.

About OBIO®

OBIO®, founded in 2009, is a not-for-profit, membership-based innovation organization engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies positioning Canada as a leader in the international marketplace. OBIO® advances this goal through collaborative partnerships with industry, the investment community, academia, the health system and government.

For media inquiries, please contact:

Bojana Duric, BlueSky Communications
bduric@blueskycommunications.com
289.981.7710

Previous
Previous

Boston Scientific Announces Agreement to Acquire Baylis Medical Company Inc.

Next
Next

OBIO Member, PhenoTips, Closes CAD $2.5M Funding Round for Software to Transform Medical Genetics